Press Releases Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:04:21 20/04/2026 pm IST			5-day change	1st Jan Change
1.825 ^USD	-8.29%		+2.23%	+35.56%

10/04	Ocugen, Inc. Announces Modifier Gene Therapy Delivers 46% Lesion Reduction in Age-Related Macular Degeneration	CI
01/04	Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of Ocu410st for Stargardt Disease	CI

Press Releases

10/04	Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells	AQ
01/04	Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease	GL
24/03	Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	GL
23/03	Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy	GL
04/03	Ocugen: Q4 Earnings Snapshot	AQ
04/03	Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results	GL
03/03	Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone	AQ
02/03	Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa	GL
18/02	Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results	GL
09/02	Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer	GL
23/01	Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock	GL
21/01	Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock	GL
15/01	Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	GL
13/01	Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data	GL
12/01	Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference	AQ
12/01	Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy	GL
09/01	Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference	GL
10/12	Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit	GL
20/11	Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference	GL
20/11	Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference	AQ
17/11	Resetting retinal networks with a gene-agnostic approach	AQ
05/11	Ocugen: Q3 Earnings Snapshot	AQ
05/11	Ocugen Provides Business Update with Third Quarter 2025 Financial Results	GL
23/25/23	Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results	GL
02/25/02	Ocugen to Present at Industry and Investor Conferences in October 2025	GL